AbbVie Inc.

(New York Stock Exchange)
Back to all articles
Somewhat Bullish +45

ABBV: SKYRIZI Approval vs Rich Valuation | ABBV Research

Analyst upgrade Drug approval Earnings report AI-generated analysis

πŸ“… On October 23, 2026, the FDA approved a subcutaneous induction regimen for SKYRIZI in Crohn's disease, expanding patient access via an on-body injector.

πŸ’° AbbVie reported Q2 2026 EPS of $3.65, beating estimates of $3.61, driven by resilient revenue from specialty biologics.

πŸ“ˆ The stock trades at a trailing P/E of 80.47 with limited implied upside to the consensus price target of $294.

⚠️ Liquidity metrics warrant monitoring as the current ratio stands at 0.81, indicating current liabilities exceed short-term assets.

πŸ† Goldman Sachs maintained a Strong Buy rating and raised its price target from $258 to $294 following the FDA action.

πŸ“… Upcoming earnings on October 30, 2026, will focus on SKYRIZI uptake, margin expansion, and capital allocation revisions.

πŸ“‰ The stock has largely stopped making Humira central to its investor narrative as it pivots toward newer assets like SKYRIZI.

Bullish Signals
  • AbbVie secured FDA approval for a subcutaneous induction regimen of SKYRIZI in Crohn's disease, expanding the label and improving patient convenience.
  • The company delivered an EPS beat of $3.65 versus estimates of $3.61 for the quarter ended July 31, 2026.
  • Goldman Sachs raised its price target to $294 following the regulatory win, signaling confidence in SKYRIZI's commercial potential.
  • AbbVie maintains a durable dividend profile and a large market capitalization while transitioning revenue streams toward newer biologics.
Risk Factors
  • Liquidity metrics are concerning with a current ratio of 0.81, indicating that current liabilities exceed short-term assets.
  • Return on equity is negative and price-to-book is negative, reflecting large share buybacks and accumulated intangible assets rather than operational weakness.
  • Implied upside to the consensus price target is only about 2.9%, suggesting the stock is fairly valued to slightly rich on a near-term basis.
Full Analysis
AbbVie (ABBV) received FDA approval on October 23, 2026, for a subcutaneous induction regimen of SKYRIZI in adults with moderately to severely active Crohn's disease. This expansion includes an on-body injector option designed to improve patient convenience and accelerate early disease control, supporting the company's medium-term revenue growth strategy as it transitions away from legacy products. Financially, ABBV reported a modest earnings beat for the quarter ended July 31, 2026, with EPS of $3.65 versus estimates of $3.61. The stock is currently trading at $285.64, near its 52-week high, but carries a trailing P/E ratio of 80.47 and limited implied upside to the consensus price target of $294, suggesting the stock is fairly valued to slightly rich on a near-term basis. Analysts maintain a constructive stance despite valuation concerns, with Goldman Sachs raising its price target to $294 following the regulatory win. However, investors are monitoring liquidity metrics, including a current ratio of 0.81 and negative return on equity, alongside upcoming earnings on October 30, 2026, which will provide critical updates on SKYRIZI uptake and capital allocation plans.